Treatment Associated Interstitial Pulmonary Toxicity of Temozolomide Plus Bevacizumab for Locally Advanced Solitary Fibrous Tumor
| Autor: | Spengler W, Biro D, Steger, Kanz L, Heissner K, Kopp Hg, Marius Horger |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Hemangiopericytoma
Chemotherapy medicine.medical_specialty Solitary fibrous tumor Temozolomide Bevacizumab Pulmonary toxicity business.industry medicine.medical_treatment medicine.disease Bioinformatics Malignancy 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Localized disease medicine 030212 general & internal medicine Radiology business medicine.drug |
| Zdroj: | Journal of Pulmonary & Respiratory Medicine. |
| ISSN: | 2161-105X |
| Popis: | Solitary Fibrous Tumors (SFT), previously termed haemangiopericytoma, are rare soft tissue sarcomas (STS). They usually grow slowly and show indolent behaviour in terms of malignancy. Surgery in localized disease is the only curative approach. While metastatic disease occurs rarely, locally advanced SFT often require systemic treatment. Systemic treatment for inoperable SFT is not standardized, and chemotherapy displays only modest activity. Temozolomide plus bevacizumab is a relatively active treatment option. Its advantages are prolonged tumor stabilisation combined with an overall low toxicity profile. We report the first case of treatment related interstitial pulmonary toxicity caused by temozolomide in combination with bevacizumab during treatment of SFT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|